Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Gables Capital Management Inc.

Gables Capital Management Inc. raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 435,421 shares of the biopharmaceutical company’s stock after purchasing an additional 26,400 shares during the period. Catalyst Pharmaceuticals accounts for approximately 3.7% of Gables Capital Management Inc.’s investment portfolio, making the stock its 4th biggest position. Gables Capital Management Inc. owned approximately 0.36% of Catalyst Pharmaceuticals worth $8,578,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Huntington National Bank raised its position in shares of Catalyst Pharmaceuticals by 105.0% during the second quarter. Huntington National Bank now owns 1,433 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 734 shares during the last quarter. Bessemer Group Inc. increased its position in Catalyst Pharmaceuticals by 331.4% during the 3rd quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,678 shares during the period. Jones Financial Companies Lllp raised its holdings in Catalyst Pharmaceuticals by 14.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 498 shares during the last quarter. Dakota Community Bank & Trust NA acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $81,000. Finally, Vinva Investment Management Ltd acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $206,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 2.2%

CPRX opened at $24.44 on Monday. The company has a fifty day moving average price of $23.59 and a two-hundred day moving average price of $21.88. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58. The company has a market cap of $3.00 billion, a P/E ratio of 14.21, a price-to-earnings-growth ratio of 0.82 and a beta of 0.74.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CPRX shares. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Oppenheimer reiterated an “outperform” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Citigroup upped their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $33.20.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Carmen Jeffrey Del sold 10,983 shares of the stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total value of $256,233.39. Following the transaction, the insider owned 3,962 shares in the company, valued at approximately $92,433.46. This represents a 73.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Molly Harper sold 26,746 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director directly owned 2,360 shares in the company, valued at $54,870. The trade was a 91.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).